Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.
Antigens, CD34
/ metabolism
Benzylamines
/ administration & dosage
Blood Component Removal
Body Weight
Cyclams
/ administration & dosage
Female
Granulocyte Colony-Stimulating Factor
/ administration & dosage
Hematopoietic Stem Cell Mobilization
/ instrumentation
Hematopoietic Stem Cell Transplantation
/ methods
Hematopoietic Stem Cells
/ cytology
Humans
Infant
Male
Pediatrics
/ methods
Receptors, Antigen, T-Cell, alpha-beta
/ metabolism
Retrospective Studies
Tissue Donors
Transplantation, Homologous
TCR-alpha/beta depletion
allogeneic
children
mobilization
plerixafor
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
21
09
2020
received:
31
03
2020
accepted:
22
02
2021
pubmed:
9
3
2021
medline:
27
1
2022
entrez:
8
3
2021
Statut:
ppublish
Résumé
Collection of a large number of early hematopoietic progenitors is essential for allogeneic apheresis products intended for TCR-alpha/beta depletion. We added plerixafor 0.24 mg/kg body weight (bw) on day 4 of high-dose filgrastim mobilization 10 hours prior to apheresis in 16 (30.5%) pediatric allogeneic donors who failed to recover a sufficient number of CD34+ cells. On day 4 of G-CSF, the median CD34+ cell count in peripheral blood was 6 per μL (range 4-9 per μL) in 6 poor mobilizers and 16 per μL (range 12-19 per μL) in insufficient mobilizers. In all donors, the threshold of 50 CD34+ cells/μL was achieved, and the median increase was 14.8-fold in poor mobilizers and 6.5-fold in insufficient mobilizers, whereas it was 3.45-fold increase in those mobilized with G-CSF alone. In all donors, a predefined number of >10 × 10 Thus, the safety and high efficacy of plerixafor was proven in healthy pediatric allogeneic hematopoietic cell donors.
Sections du résumé
BACKGROUND
BACKGROUND
Collection of a large number of early hematopoietic progenitors is essential for allogeneic apheresis products intended for TCR-alpha/beta depletion.
MATERIALS AND METHODS
METHODS
We added plerixafor 0.24 mg/kg body weight (bw) on day 4 of high-dose filgrastim mobilization 10 hours prior to apheresis in 16 (30.5%) pediatric allogeneic donors who failed to recover a sufficient number of CD34+ cells.
RESULTS
RESULTS
On day 4 of G-CSF, the median CD34+ cell count in peripheral blood was 6 per μL (range 4-9 per μL) in 6 poor mobilizers and 16 per μL (range 12-19 per μL) in insufficient mobilizers. In all donors, the threshold of 50 CD34+ cells/μL was achieved, and the median increase was 14.8-fold in poor mobilizers and 6.5-fold in insufficient mobilizers, whereas it was 3.45-fold increase in those mobilized with G-CSF alone.
DISCUSSION
CONCLUSIONS
In all donors, a predefined number of >10 × 10
CONCLUSION
CONCLUSIONS
Thus, the safety and high efficacy of plerixafor was proven in healthy pediatric allogeneic hematopoietic cell donors.
Substances chimiques
Antigens, CD34
0
Benzylamines
0
Cyclams
0
Receptors, Antigen, T-Cell, alpha-beta
0
Granulocyte Colony-Stimulating Factor
143011-72-7
plerixafor
S915P5499N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
547-552Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Lickliter JD, Begley CG, Boyd AW, Szer J, Grigg AP. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients. Leuk Lymphoma. 1994;15(1-2):91-97.
Sung AD, Grima DT, Bernard LM, et al. Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplant. 2013;48(11):1444-1449.
DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726. https://doi.org/10.1182/blood-2008-08-174946.
Russell N, Douglas K, Ho AD, et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica. 2013;98(2):172-178. https://doi.org/10.3324/haematol.2012.071456.
Hartmann T, Hübel K, Monsef I, Engert A, Skoetz N. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilization for autologous transplantation in people with malignant lymphoma or multiple myeloma. Cochrane Database Syst Rev. 2015;10:CD010615. https://doi.org/10.1002/14651858.CD010615.pub2.
Modak S, Cheung IY, Kushner BH, Kramer K, Reich L, Cheung NK. Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. Pediatr Blood Cancer. 2012;58:469-471.
Vettenranta K, Möttönen M, Riikonen P. The use of plerixafor in harvesting autologous stem cells in the pediatric setting. Pediatr Blood Cancer. 2012;59:197-198.
Maschan AA, Balashov DN, Kurnikova EE, et al. Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF. Bone Marrow Transplant. 2015;50(8):1089-1091. https://doi.org/10.1038/bmt.2015.71.
Rutella S, Filippini P, Bertaina V, et al. Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts. J Transl Med. 2014;12:240. https://doi.org/10.1186/s12967-014-0240-z.
Gattillo S, Marktel S, Rizzo L, et al. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. Transfusion. 2015;55(8):1993-2000. https://doi.org/10.1111/trf.13059.
Pantin J, Purev E, Tian X, et al. Effect of high-dose plerixafor on CD34(+) cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102(3):600-609. https://doi.org/10.3324/haematol.2016.147132.
Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hemototherapy and Graft Engineering. J Hematother. 1996;5:213-226.
Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E. Prediction of mobilization failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2004;33:907-912.
Micallef IN, Apostolidis J, Rohatiner AZ, et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J. 2000;1(6):367-373.
Jaiswal SR, Bhakuni P, Joy A, et al. Impact of single-dose Plerixafor as an adjunct to granulocyte Colony-stimulating factor-based peripheral blood stem cell mobilization on the graft composition and outcome for T cell-replete Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide: a comparative study. Biol Blood Marrow Transplant. 2018;24(3):542-548. https://doi.org/10.1016/j.bbmt.2017.11.014.
Gaugler B, Arbez J, Legouill S, et al. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. Cytotherapy. 2013;15(7):861-868. https://doi.org/10.1016/j.jcyt.2013.03.013.
Teipel R, Oelschlägel U, Wetzko K, et al. Differences in cellular composition of peripheral blood stem cell grafts from healthy stem cell donors mobilized with either granulocyte Colony-stimulating factor (G-CSF) alone or G-CSF and Plerixafor. Biol Blood Marrow Transplant. 2018;24(11):2171-2177. https://doi.org/10.1016/j.bbmt.2018.06.023.